Introduction
Dysregulation of cell cycle is one of the important mechanisms for uncontrolled growth in most cancers. p27 Kip1 , a cyclin-dependent kinase (cdk) inhibitor, inhibits the transition from G1 to S phase by suppressing the activity of a cyclin E/cdk2 complex in the late G1 to S phase. 1 In many cancers, including gastric, breast and colorectal cancers, low expression of p27 Kip1 was reported to be associated with poor prognosis and highly aggressive nature of the tumors. 2 Since the level of the p27 Kip1 protein is mainly controlled by ubiquitinproteosomal proteolysis, enhanced degradation of p27 Kip1 appeared to be an important mechanism for the reduction of p27 Kip1 in cancers. 3 Skp-2, a member of the F-box protein family, is a specific substrate-recognition subunit of an SCF ubiquitin-protein ligase complex and is involved in the p27 Kip1 degradation. 4 Increased expression of Skp-2, accompanied by inverse decrease of p27 Kip1 , was reported in many cancers, including small-cell lung carcinoma (SCLC), 5 oral squamous cell carcinoma, 6 lymphoma 7 or gastric carcinoma, 2 indicating that Skp-2 may be involved in the tumorigenesis of some cancers with the reduced p27 Kip1 . The Skp-2 was overexpressed in 44% of primary SCLC with the reduced expression of p27 Kip1 through the gene amplification in 5p11-13. 5 Yokoi et al 5, 8 have previously shown that downregulation of Skp-2 in an SCLC cell line with antisense oligonucleotides resulted in the inhibition of in vitro cell growth. However, the precise mechanism of growth inhibition by the Skp-2 inactivation remains to be investigated. In this study, we have analyzed the mechanism for the inhibition of tumor cell growth using newly developed HIV and adenoviral vectors expressing the Skp-2 siRNA, which may be useful for the future gene therapy.
Results
HIV vector-mediated RNA interference (RNAi) for Skp-2 resulted in the inhibition of in vitro cell growth of SCLC cell line with elevated Skp-2 expression
We constructed several HIV vectors expressing siRNAs targeting at the Skp-2 mRNA and analyzed their RNAi effects by determining the Skp-2 protein by Western blot analysis after infecting an SCLC cell line, ACC-LC-172, which has the gene amplification and increased expression of Skp-2. Of these siRNA HIV vectors, we selected two HIV vectors, S2 and S5, which mediated efficient reduction of the Skp-2 protein. We next evaluated effects of the RNAi for Skp-2 on in vitro growth of the ACC-LC-172 SCLC cells by infection of these Skp-2 siRNA HIV vectors and a control siRNA HIV vector for firefly lucifrase (GL3B) whose infection did not affect in vitro growth, cell cycle status and amounts of Skp-2 protein of ACC-LC-172 compared to uninfected ACC-LC-172 (data not shown). In vitro cell growth of ACC-LC-172 was significantly inhibited when infected with the S5 siRNA HIV vector compared to the control GL3B siRNA HIV vector (Po0.0001), although transduction efficiency monitored by GFP-expressing cells was comparable among the infected cells (98.7-99.9%). (Figure 1a ). The similar cell growth inhibition was observed in a melanoma cell line, A375mel, with the overly expressed Skp2 (data not shown). In vitro growth of ACC-LC-172 infected with the S2 siRNA HIV vector was less inhibited than that with S5 (P ¼ 0.0005) (Figure 1a) , associated with the weaker suppression of Skp-2 and less induction of p27 Kip1 and p21 compared to S5 (Figure 1b) . The decrease of the Skp-2 protein accompanied by the reduction of p27 Kip1 protein, shown by Western blot analysis of cell lysates at day 9 after the infection, was positively correlated with the inhibition of in vitro cell growth (Figure 1a and b). Other cdk inhibitor p21 was slightly elevated in the cells infected with the S2 and S5 siRNA HIV vectors similarly with p27 Kip1 ( Figure 1b ). The p57 Kip2 protein was under the detectable limit in this cell line (data not shown). The Rb protein was not changed after the infection. Cell cycle analysis performed on day 9 after the infection demonstrated decrease of the population in S and G2/M phases in the cells infected with the S5 siRNA HIV vector (44.6%) compared to those infected with the GL3B siRNA HIV vector (57.1%) ( Table 1) . No significant apoptosis was observed in the infected cells by flow cytometry analysis and DNA fragmentation assays (data not shown). These results indicated that the Skp-2 RNAi inhibited cellular growth of ACC-LC-172 through the increase of both cdk inhibitors p27 Kip1 and p21. In contrast, in vitro growth of 293T cells without the Skp-2 overexpression was less sensitive to the inhibitory effect of the Skp-2 RNAi (P ¼ 0.1835) (Figure 2a) , although similar pattern of changes was observed in the Skp-2 and p27 Kip1 proteins (Figure 2b ). The constitutively low-level expression of the Skp-2 in 293T cells may explain the reason for the 293T resistance to the Skp-2 RNAi ( Figure  2c ). Similarly, in vitro cell growth of SBC-1, an SCLC cell line that lacks detectable Skp-2 expression, was not inhibited by the Skp-2 siRNAs (Figure 2d ). Thus, virally mediated Skip2 RNAi does not appear to affect cells with low Skp2 expression.
Less involvement of myc in the inhibition of the ACC-LC-172 cell growth by the Skp-2 RNAi Since Skp-2 was also reported to act as a transcriptional cofactor for c-myc, 9, 10 which is involved in cell cycle progression by mediating the activation of cyclin E-cdk2 and cyclin D-cdk4, promoting the G1/S transition, 11 we evaluated the role of myc in the Skp-2 RNAi-mediated cell growth inhibition of the ACC-LC-172 SCLC cells. Increased myc expression was previously reported in most SCLC 11 and mild myc increase (2.03-fold) was detected in ACC-LC-172 (data not shown).
When a firefly luciferase expression plasmid, whose expression is under the control of human telomerase reverse transcriptase (hTERT) gene promoter containing Figure 1 Inhibition of in vitro growth of an SCLC cell line along with decrease of Skp-2 and increase of p27 Kip1 and p21 by infection of the HIV vectors expressing siRNA for Skp-2: (a) inhibition of in vitro tumor cell growth by virally medicated RNAi for Skp-2. SCLC cell line ACC-LC-172 (100 000) were infected with siRNA HIV vectors for control firefly luciferase (GL3B) or Skp-2 mRNA (S2 and S5) at 100 MOI on day 0, then the cell numbers were determined by trypan blue dye exclusion method on days 3, 6 and 9. The vertical bars indicate the s.d. of the triplicate assays (*P ¼ 0.0005; **Po0.0001). This is one representative result of three independent experiments with similar results. (b) Decrease of Skp-2 protein and increase of p27 Kip1 and p21 proteins by virally medicated RNAi for Skp-2. Cell lysates were prepared from the cells infected with siRNA HIV vectors in (a) on day 9 after the infection. The Skp-2 protein was significantly decreased in cells infected with S2 and S5 compared to GL3B, and p27 Kip1 and p21 proteins were reciprocally increased in cells infected with S2 and S5. The degrees of the increase of the p27 Kip1 and p21 proteins were correlated with the degrees of the decrease of the Skp-2 protein. The transduction efficiency determined by GFP expression by flow cytometry was equivalent among the three groups (98.7-99.9%) at the harvest. Cancer gene therapy by Skp-2 RNA interference H Sumimoto et al two myc-binding E-box (CACGTG) motifs 12 (pGL3-hTERT), was transiently transfected to ACC-LC-172, the firefly luciferase activity normalized by Renilla luciferase activity was only minimally increased (1.1-to 2.7-fold) compared to that with a pGL3-Basic plasmid (Figure 3 ), suggesting that constitutive myc activity was relatively low in the ACC-LC-172 cells. Transfection of the same plasmid into the ACC-LC-172 cells stably transduced with the HIV Skp-2 siRNA vector (siRNA S5) did not change the luciferase activity. These results indicated that enhancement of myc activity was not the mechanism for the cell growth inhibition of ACC-LC-172 by the Skp-2 RNAi.
In vivo therapeutic activity of intratumoral administration of adenovirus siRNA for Skp-2
To evaluate therapeutic ability of the RNAi for Skp-2, we constructed an adenovirus vector expressing siRNA for Kip1 protein by the Skp-2 siRNA HIV vector infection. Cell lysates were prepared as in Figure  1b . Relatively low expression Skp-2 protein was decreased in cells infected with S5 compared to GL3B, and the p27 Kip1 protein was reciprocally increased in cells infected with S5, although the changes were less prominent than observed in ACC-LC172 cells. The transduction efficiency determined by GFP expression by flow cytometry was equivalent between the two groups (GL3B: 95.4%; S5: 100.0%) at the harvest. At 48 h after the transfection, the cells were harvested and the both Renilla and firefly luciferase activities were determined. Each firefly luciferase activity normalized by the Renilla luciferase activity was calculated. The normalized firefly luciferase activity with pGL3-hTERT was minimally elevated by 1.6-fold compared to with pGL3-Basic without any inhibition in the presence of siRNA for Skp-2. Each bar represents the mean value of triplicate assays and error bars represent the s.d. This is one representative result of three independent experiments with similar results.
Cancer
Skp-2, AdF35-Skp-2 siRNA S5, since adenovirus vector is more effective for in vivo gene transfer with more efficient production of high-titer viruses. The constructed adenovirus reduced the Skp-2 protein very efficiently in the ACC-LC-172 SCLC cells at only 5 multiplicity of infection (MOI) (Figure 4a) , and inhibited the cell growth compared with the control AdF35-GL3B (data not shown). When these adenoviruses were intratumorally injected three times every 2 days to subcutaneously grown ACC-LC-172 SCLC tumors with the largest diameter of 3-4 mm on immunodeficient NOD/SCID mice, growth of tumors injected with the AdF35-Skp-2 siRNA (S5) was significantly reduced compared to that with the control AdF35-GL3B (Po0.05) (Figure 4b ). These results indicated that Skp-2 is an excellent target for the treatment of cancers with the increased Skp-2, and gene therapy by virally mediated RNAi may be applicable for these cancers.
Discussion
The cdk inhibitor, p27 Kip1 , controls progression of cell cycles in response to mitogenic stimuli, and is a dosagedependent tumor suppressor protein. 3 Reduced expression of p27 Kip1 is not usually caused by genetic change, 3 but often caused by enhanced proteolysis in cancers. The targeted disruption of an ubiquitin-protein ligase Skp-2 resulted in cell cycle arrest in G1 with the accumulation of p27 Kip1 , 13 indicating that Skp-2 regulate cell cycle progression through proteolysis of p27 Kip1 . Patients with cancers with the reduced p27 Kip1 by increased expression of Skp-2 were reported to have relatively poor prognosis in clinical studies. [6] [7] [8] In this study, we attempted virally mediated RNAi for Skp-2 on the SCLC cell line to analyze the role of Skp-2 in the cell growth as well as to develop possible gene therapy for the Skp-2 overexpressing cancers. The observation that cell growth was inhibited by the virally mediated Skp-2 RNAi, which was accompanied by downregulation of Skp-2 and upregulation of both p27 Kip1 and p21, indicated that the increased Skp-2 expression is a primary event causing cell cycle progression of the SCLC cell line through the enhanced proteolytic degradation of p27 Kip1 . Interestingly, the degree of the Skp-2 suppression with different siRNAs was correlated with the degree of the elevation of p27 Kip1 and p21 as well as in vitro growth suppression. Although p21 is mainly regulated transcriptionally, Skp-2-mediated ubiquitination and the subsequent proteolysis appear to be involved in the regulation of p21. 14 Although the increase of p21 was not as prominent as that of p27 Kip1 , we also observed significant increase of p21 after the Skp-2 RNAi, indicating that it may also contribute to the cell cycle progression in the SCLC cell line.
Although Yokoi et al reported that antisense oligonucleotide-mediated inactivation of Skp-2 resulted in the induction of apoptosis characterized by an increase of the sub-G1 population, fragmentation of nuclei and activation of caspase-3 when evaluated on days 2-4, 8 we did not observe significant increase of the sub-G1 population or DNA fragmentation in the ACC-LC-172 cells with the siRNA HIV vectors in spite of very efficient downregulation of Skp-2 on day 9 (data not shown). This discrepancy may result from the different time point. Remaining on day 9 after the lentiviral infection cells might have been refractory to the apoptotis.
In contrast to the previous reports using Skp-2 À/À mice 13 or forced expression of p27 Kip1 , 1 Skp-2 RNAi did not lead to complete G1 arrest. Although almost complete downregulation of the Skp-2 protein accompanied by the increase of the p27 Kip1 protein was observed with the siRNA S5 (Figure 1b) , these infected cells continued to grow slowly (Figure 1a) , possibly due to relative resistance of this cell line to cell cycle inhibition by p27 Kip1 .
In terms of possible use of this strategy for treatment of cancer patients, along with the effective tumor growth inhibition, it should be noted that growth of cells without the increased Skp-2, including 293T cells and primary fibroblasts (data not shown) was hardly affected by Skp-2 RNAi, suggesting that inactivation of Skp-2 is a relatively safe targeting therapy for cancers with high Skp-2 expression. In this study, we also demonstrated 
Materials and methods

Cell lines
An ACC-LC-172 cell line (a kind gift from Dr Takahashi, Aichi Cancer Center, Research Institute, Japan) and SBC-1 (purchased from Japanese Collection of Research Bioresources, Japan) established from Japanese patients with SCLC were maintained in RPMI-1640 (Sigma, Japan) supplemented with 10% (v/v) fetal bovine serum, penicillin and streptomycin. The 293T cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in DMEM (Sigma, Japan) supplemented with 10% (v/v) fetal bovine serum, penicillin and streptomycin.
HIV vectors
HIV vectors for siRNA expression were constructed from an HIV-U6i-GFP plasmid, which was described previously. 15, 16 Briefly, HIV-U6i-GFP has two expression units: one was an siRNA expression cassette, from which a short hairpin RNA was transcribed from human U6 promoter, and the second was a GFP expression cassette, from which GFP gene was transcribed from the CMV promoter. For siRNA expression, in vitro annealed complementary oligonucleotides for target sequences were inserted into the two BspMI sites downstream of the human U6 promoter. Two siRNA target sequences were selected for the Skp-2 RNAi: (S2) ATCA GATCTCTCTACTTTA and (S5) AGGTCTCTGGTGTTT GTAA. Two complementary oligonucleotides, cacc-(target sense)-TTCAAGAGA-(target antisense)-TTTTT and gcatAAAAA-(target sense)-TCTCTTGAA-(target antisense) were synthesized for each target sequence and annealed in vitro. The annealed double-stranded (ds) oligonucleotides with 5 0 -protruding ends complementary to the two BspMI sites in the HIV-U6i-GFP plasmid were then subcloned into the HIV-U6i-GFP. Control GL3B siRNA (anti-firefly luciferase siRNA) HIV vector was also constructed with the target sequence GTGCGCTGCTGGTGCCAAC. A mutation-specific anti-BRAF siRNA HIV vector (target: GCTACAGA GAAATCTCGATGG) was used for control in a reporter assay. These HIV vectors produce a short hairpin RNA with the linker sequence (TTCAAGAGA) forming a loop structure, then the linker is processed by Dicer, forming a dsRNA that act as an siRNA. The third-generation HIV vectors were produced by transfecting 293T cells with HIV plasmid vectors, pMD.G (VSV-G env expression plasmid), pMDLg/p.RRE (the third-generation packaging plasmid) and pRSV Rev (Rev expression plasmid) (the latter two plasmids were provided by Cell Genesys, USA) by calcium phosphate transfection. The culture supernatants were collected and used as virus stocks after concentration. The viral titer was measured by counting GFP-positive cells after infection on 293T cells.
In vitro growth inhibition assay
ACC-LC-172 cells (100 000) were infected with the siRNA HIV vectors for Skp-2 (S2 or S5) or firefly luciferase (GL3B) at 100 MOI at day 0. Cell numbers were counted every 3 days by trypan blue dye exclusion method until day 9. The 293T cells (30 000) were infected with siRNA HIV vectors for control GL3B or Skp-2 (S5) at 100 MOI at day 0, then the cell numbers were determined every 3 days until day 9. SBC-1 cells (100 000) were infected with the siRNA HIV vectors, S2, S5 or GL3B at 100 MOI. Cell numbers were counted every 4 days until day 8.
Western blot analysis
Cell lysates were prepared in the lysis buffer (20 mM TrisHCl (pH 7.5), 12.5 mM b-glycerophosphate, 2 mM EGTA, 10 mM NaF, 1 mM benzamide, 1% NP-40, protease inhibition cocktail (complete, EDTA-free (Roche, Germany)) and 1 mM Na 3 VO 4 ) from the infected cells used in in vitro growth inhibition assay on day 9 after confirmation of equivalent GFP expression among the groups by flow cytometry. The protein concentration was determined by DC protein assay kit (Bio-Rad, USA). Anti-p45
SkpÀ2 (Zymed Laboratories Inc., CA, USA), antiactin (Sigma, USA), anti-p27 Kip1 (BD Transduction, USA), anti-Rb (Cell Signaling, USA) or anti-p21 (Santa Cruz, USA) Abs was used for the first antibody. An HRPconjugated anti-IgG antibody was used for the second antibody, and the reaction was detected by chemiluminescence with SuperSignal West Femto Maximum Sensitivity Substrate (Pierce, USA).
Cell cycle analysis
The cells used in the in vitro growth inhibition assays were harvested on day 9 and stained with propidium iodide (PI) by using CycleTEST PLUS DNA Reagent Kit (Becton Dickinson, San Jose, CA, USA) according to the manufacturer's instruction. After the stained cells were analyzed by FACSCalibur (Becton Dickinson), the cell cycle status was analyzed with ModFit software (Becton Dickinson).
hTERT reporter construction A 0.4 kb hTERT promoter sequence was amplified by genomic PCR with the forward primer: CGCTGG GGCCCTCGC TGGCGTCCCT (nts À324 to À300, numbered relative to the translation initiation site); and the reverse primer: CAGCGGCAGCACCTCGCGGTAGTGG (nts +48 to +72). After denaturation for 4 min at 951C, 27 cycles of denaturation for 1 min at 951C, annealing for 1 min at 701C and extension for 1 min at 721C were performed and followed by completion for 7 min at 721C. The PCR product was subcloned into a pCRII vector of TA Cloning kit (Invitrogen, San Diego, CA). After the confirmation of the correct sequence, the translation initiation codon was mutated from ATG to TTG by using QuikChange site-directed mutagenesis kit (STRATA-GENE, La Jolla, CA, USA). Then, the hTERT promoter was subcloned into a pGL3-Basic vector (Promega, Madison, WI, USA). The resultant construct, pGL3-hTERT, transcribes the firefly luciferase gene under the control of the 0.4 kb hTERT promoter.
Reporter assay
ACC-LC-172 cells (500 000) stably expressing siRNA for Skp-2 (S5) or for BRAF (V599E) (control siRNA specific Cancer gene therapy by Skp-2 RNA interference H Sumimoto et al for mutated BRAF (V599E) after the infection with HIV vectors) were transfected with 1 mg of Renilla luciferase expression plasmid, pRL-SV40 (Promega) and 1 mg of one of the following firefly luciferase expression plasmids: pGL3-hTERT, pGL3-Basic or pGL3-control (Promega) by using Lipofectamine (Invitrogen). At 48 h after the transfection, the cells were harvested and the luciferase activity was analyzed using Dual-Glo Luciferase Assay System (Promega) and a Berthold luminometer. Each firefly luciferase activity was normalized to Renilla luciferase activity.
Adenovirus vectors for siRNA
The adenovirus vectors containing Ad5/35 chimeric fiber protein 17 were used in this study. The vector plasmids pAdF35 and the shuttle vector plasmid pHMCMV-GFP1 were described previously. 18 pHMCMV-GFP1 contains the CMV promoter, the GFP gene derived from pEGFP-N1 (Clontech, Palo Alto, CA, USA) and the bovine growth hormone (BGH) poly(A) signal. The siRNA expression unit containing human U6 promoter and two BspMI cloning sites were excised from the HIV-U6i-GFP plasmid by EcoRI digestion, then subcloned into the EcoRI site in pHMCMV-GFP1, which was located downstream of the BGH poly(A) signal. This vector was designated as pHMCMV-GFP-U6i. The ds oligonucleotides for the short hairpin RNA can be directly subcloned into the two BspMI sites of the pHMCMV-GFP-U6i as in HIV-U6i-GFP. Accordingly, the shuttle vector plasmids containing ds oligonucleotides for Skp-2 (S5) or GL3B were constructed. The adenovirus vectors, AdF35-Skp-2 siRNA S5 and AdF35-GL3B, were constructed by an improved in vitro ligation method as described. 19 Both adenovirus vectors were propagated in 293 cells and the viral titers were determined using Adeno-X Rpaid Titer Kit (Clontech) according to the manufacturer's instructions.
Animal experiments
Male NOD/SCID mice (6 weeks old) (Japan Clea, Japan) were subcutaneously implanted with 5 Â 10 6 ACC-LC-172 cells. About 1 week after the implantation, when the largest tumor diameter reached about 3-4 mm, we injected 1 Â 10 8 IFU of AdF35-Skp-2 siRNA S5 or AdF35-GL3B into the tumor (day 0). The adenovirus injection was repeated twice every 2 days. The tumor volume (the largest diameter Â the perpendicular diameter Â the height) was measured every 2 or 3 days until day 13. The animal experimental protocol was approved by the Laboratory Animal Care and Use Committee at Keio University School of Medicine. Mice were treated according to the Guidelines for the Care and Use of Laboratory Animals of Keio University School of Medicine.
Statistical analysis
All statistical analyses were performed according to unpaired Student's t-test.
